The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Quest Diagnostics, Inc shares valued at $153,579 were sold by DELANEY MARK E on May 12 ’25. At $175.72 per share, DELANEY MARK E sold 874 shares. The insider’s holdings dropped to 8,372 shares worth approximately $1.46 million following the completion of this transaction.
Also, DELANEY MARK E sold 874 shares, netting a total of over 153,221 in proceeds. Following the sale of shares at $175.31 each, the insider now holds 7,498 shares.
Before that, DELANEY MARK E had added 874 shares to its account. In a trade valued at $153,221, the Officer bought Quest Diagnostics, Inc shares for $175.31 each.
As published in their initiating research note from Redburn Atlantic on April 02, 2025, Quest Diagnostics, Inc [DGX] has been a Buy and the price target has been revised to $195. Analysts at Citigroup downgraded the stock from ‘”a Buy”‘ to ‘”a Neutral”‘ outlook in a report released in early March. As of January 06, 2025, Leerink Partners has increased its “Market perform” rating to a “an Outperform” for DGX. Earlier on December 17, 2024, Morgan Stanley upgraded its rating. Their new recommendation was “an Overweight” for DGX stock which previously was a “an Equal-weight”.
Analyzing DGX Stock Performance
During the last five days, there has been a surge of approximately 1.42%. Over the course of the year, Quest Diagnostics, Inc shares have jumped approximately 15.21%. Shares of the company reached a 52-week high of $179.99 on 05/20/25 and a 52-week low of $148.70 on 01/16/25.
Support And Resistance Levels for Quest Diagnostics, Inc (DGX)
According to the 24-hour chart, there is a support level at 172.68, which, if violated, would cause prices to drop to 171.56. In the upper region, resistance lies at 175.10. The next price resistance is at 176.40. RSI (Relative Strength Index) is 50.95 on the 14-day chart, showing neutral technical sentiment.
